Form 10-Q Opexa Therapeutics, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Opexa Therapeutics (OPXA) Tops Q1 EPS by 4c
May 12, 2016 4:57 PM EDTOpexa Therapeutics (NASDAQ: OPXA) reported Q1 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $726.3 thousand versus the consensus estimate of $400 thousand.
Financial Guidance
Based on the current activities of the Company and projected... More
